Logo

PharmaCyte Initiates the First Phase of the Two-Phase Study Evaluating CypCaps to Lift the US FDA’s Clinical Hold

Share this
PharmaCyte Initiates the First Phase of the Two-Phase Study Evaluating CypCaps to Lift the US FDA’s Clinical Hold

PharmaCyte Initiates the First Phase of the Two-Phase Study Evaluating CypCaps to Lift the US FDA’s Clinical Hold

Shots:

 

  • PharmaCyte initiated the 1st phase of the study which evaluates the microcatheter-based delivery of CypCaps inj. (100) in the pancreatic arterial system of Yorkshire pigs (n=2, 90 Lbs.) using its Cell-in-a-Box technology. Fluoroscopy will be used to study the vascular anatomy, treatment site suitability & acute deployment characteristics
  • The results of the 1st phase study will aid the final protocol generation for the 2nd phase study that will be presented to the US FDA for review & guidance
  • The company is performing these 2 phased studies to lift the clinical hold on the P-IIb trial evaluating CypCaps under its Cell-in-a-Box technology to treat LAPC. Both the studies are being conducted by CBSET

Ref: Bussinesswire | Image: PharmaCyte

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions